Vaccines
From the Journals
Safety remains top parent concern for HPV vaccine
Though parents’ concerns about safety and side effects have increased for the HPV vaccine, other reasons for declining the vaccine have decreased...
Photo Rounds
Severe rash after COVID-19 vaccination
The patient’s recent vaccine was the most remarkable thing about his medical history.
Feature
Here’s how we can rebuild trust in vaccines
“Even if it’s the wildest conspiracy theory I’ve ever heard, that is my opportunity to show them that I’m listening and to empathize.”
Latest News
Study of hospitalizations in Canada quantifies benefit of COVID-19 vaccine to reduce death, ICU admissions
Unvaccinated patients were found to be up to 15 times more likely to die from COVID-19 than fully vaccinated patients.
Conference Coverage
New drugs in primary care: Lessons learned from COVID-19
Nirmatrelvir-ritonavir has helped keep many patients out of the hospital, says internist.
News from the FDA/CDC
FDA approves first RSV vaccine for older adults
Older adults with underlying health conditions, such as lung or heart disease, are at high risk for severe disease.
Conference Coverage
‘Exciting’ results for cancer vaccine plus pembro in melanoma
A new randomized study is the first to demonstrate improvement in recurrence-free survival in melanoma with an individualized neoantigen vaccine...
News from the FDA/CDC
CDC backs FDA’s call for second COVID booster for those at high risk
The agency is following the recommendations made by its Advisory Committee on Immunization Practices (ACIP).
Latest News
Cancer, heart disease vaccines may be ready by 2030, Moderna says
The announcement is yet another sign of what many are calling “the golden age” of vaccine development.
Conference Coverage
Parents of patients with rheumatic disease, MIS-C strongly hesitant of COVID vaccination
A single-center study and a survey of rheumatologists revealed similar levels of hesitancy among parents of both these populations.
Commentary
Why 9 is not too young for the HPV vaccine
The response to the two-dose series of HPV in preadolescents is robust and long-lasting, with no downside to giving it a few years earlier.